在肝细胞癌中,PPM1G通过调节突变GOF p53蛋白表达来促进细胞增殖
Wen Hu1, Shao-Lin Ma2, Liang Qiong1
1Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, China.
iScience
|February 22, 2024
概括
蛋白酸酶Mg2+/Mn2+依赖性1G (PPM1G) 在肝细胞癌 (HCC) 中过度表达,与患者生存率差相关. PPM1G通过与突变p53.3相互作用,促进HCC细胞增殖和瘤生长.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 氨酸/氨酸蛋白酸酶调节关键的细胞功能.
- 蛋白酸酶Mg2+/Mn2+依赖1G (PPM1G) 在肝细胞癌 (HCC) 中的作用尚不清楚.
- 突变p53经常在包括HCC在内的各种癌症中观察到,并且可以驱动瘤发生.
研究的目的:
- 研究PPM1G在肝细胞癌中的作用和临床意义.
- 探索PPM1G在HCC中的功能背后的分子机制.
- 评估PPM1G作为潜在的预后生物标志物和HCC的治疗标.
主要方法:
- 定量实时PCR和西部抹迹测试用于评估HCC组织和细胞系中的PPM1G表达.
- 基于PPM1G表达水平的HCC患者的生存分析.
- 细胞增殖测定和体内瘤异种移植模型,以评估PPM1G的功能影响.
- 免疫沉试验用于调查PPM1G和突变p53.3之间的相互作用.
主要成果:
- 与正常肝脏组织相比,PPM1G在HCC组织和细胞中显著过度表达,无论是RNA还是蛋白质水平.
- 高PPM1G表达与HCC患者的总生存时间和无病生存时间较短密切相关.
- 增强的PPM1G表达加速了HCC细胞的增殖,并在体内增加了瘤体积.
- 上调的PPM1G增加了功能获取 (GOF) 突变p53的蛋白质水平,通过免疫沉证实了直接相互作用.
结论:
- PPM1G是肝细胞癌的关键致癌因子.
- 过度表达PPM1G作为HCC患者的显著负面预后预测剂.
- PPM1G与突变p53的相互作用凸显了它在HCC进展中的作用,并建议它作为潜在的治疗点.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


